Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians and a service of AmeritoxSM, today announced it has commissioned a research study by the UCLA Center for Health Services and Society that will help establish the first clinical guidelines for the use of urine drug monitoring among behavioral health patients who have been diagnosed with a serious mental illness. The research for the study has been completed, and the analysis is forthcoming.
“Using urine drug monitoring is still a very new concept in behavioral health, and this study will give us a solid understanding of how clinicians are utilizing it now, and how it’s helping those same clinicians in treating their patients,” said Ameritox Chief Medical Officer Thomas Smith, MD.
The UCLA Center for Health Services and Society was selected for their expertise in enhancing the health of communities; access to and quality of care; and qualitative research. All Center publications undergo a rigorous peer review process to verify the accuracy of findings and to gauge their relevance and utility to intended audiences.
The research findings will be announced by both Ameritox and the UCLA Center for Health Policy Research. Please visit http://hss.semel.ucla.edu for more information about this research institution.
About Ingenuity Health
As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness.